Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Right To Try topic
No spam. Unsubscribe anytime.
Committee advances Senate File 56 to expand Right-to-Try access and civil liability protections
Summary
Senate File 56, described as the "Iowa Right to Try Act 2," would expand the state's 2017 right-to-try framework to allow access to unapproved or preclinical treatments in certain cases; the committee approved the bill and advanced it to the calendar.
Senator Lanz, sponsor of Senate File 56, told the Health and Human Services Committee the bill is branded the "Iowa Right to Tri Act 2" and would add to the state's 2017 right-to-try law. Lanz described the measure as creating options "where we have patients that really are at the end of the rope and there is no treatment available" and said the bill includes liability protections for providers.
Why it matters: The bill affects seriously ill patients seeking access to experimental or not-yet-approved treatments and clarifies liability protections for medical providers and others who participate in such access within the state.
Details from committee: Lanz said she has been preparing a small amendment to clarify protections and who is covered. She described the proposal as intended to cover situations when a potential treatment is "in preclinical trial or ... not in a situation that is fully approved" and would allow patients to pursue such options within Iowa under defined conditions.
Subcommittee action and next steps: Lanz reported a subcommittee including herself, Senator Klimesh, and Senator Accelsi had signed off. Lanz moved the bill and the committee approved advancing Senate File 56; the chair announced the bill will move to the calendar under Rule 40.
Ending note: The sponsor said additional drafting work on a modest amendment was ongoing; the committee advanced the bill to the full Senate calendar.
